User profiles for "author:Adnan Khattak"
Adnan KhattakEdith Cowan University Verified email at health.wa.gov.au Cited by 4339 |
[HTML][HTML] Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer
Background The role of adjuvant chemotherapy in stage II colon cancer continues to be
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …
debated. The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor …
[HTML][HTML] Adjuvant pembrolizumab versus placebo in resected stage III melanoma
Background The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to
prolong progression-free and overall survival among patients with advanced melanoma. We …
prolong progression-free and overall survival among patients with advanced melanoma. We …
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double …
Summary Background The European Organisation for Research and Treatment of Cancer
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …
(EORTC) 1325/KEYNOTE-054 trial assessed pembrolizumab versus placebo in patients …
Impact of the COVID-19 pandemic on cancer care: a global collaborative study
AR Jazieh, H Akbulut, G Curigliano, A Rogado… - JCO global …, 2020 - ascopubs.org
PURPOSE The COVID-19 pandemic affected health care systems globally and resulted in
the interruption of usual care in many health care facilities, exposing vulnerable patients with …
the interruption of usual care in many health care facilities, exposing vulnerable patients with …
[HTML][HTML] Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325 …
PURPOSE We conducted the phase III double-blind European Organisation for Research
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …
and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab …
Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or …
AMM Eggermont, M Kicinski, CU Blank… - JAMA …, 2020 - jamanetwork.com
Importance Whether immune-related adverse events (irAEs) indicate drug activity in patients
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the …
treated with immune checkpoint inhibitors remains unknown. Objective To investigate the …
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Background Systemic adjuvant treatment might mitigate the high risk of disease recurrence
in patients with resected stage IIC–III melanoma. The BRIM8 study evaluated adjuvant …
in patients with resected stage IIC–III melanoma. The BRIM8 study evaluated adjuvant …
Five-year analysis of adjuvant pembrolizumab or placebo in stage III melanoma
AMM Eggermont, M Kicinski, CU Blank… - NEJM …, 2022 - evidence.nejm.org
Background In the previously reported primary analyses of this phase 3 trial, 12 months of
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …
adjuvant pembrolizumab resulted in significantly longer recurrence-and distant metastasis …
[HTML][HTML] Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
Background To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of
eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with …
eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, in combination with …
KEYNOTE–D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma
Despite improvements made with checkpoint inhibitor (CPI) therapy, a need for new
approaches to improve outcomes for patients with unresectable or metastatic melanoma …
approaches to improve outcomes for patients with unresectable or metastatic melanoma …